182 related articles for article (PubMed ID: 38275415)
21. Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.
Colombo C; Muzza M; Proverbio MC; Ercoli G; Perrino M; Cirello V; Vicentini L; Ferrero S; Fugazzola L
Clin Endocrinol (Oxf); 2017 Jun; 86(6):837-844. PubMed ID: 28222214
[TBL] [Abstract][Full Text] [Related]
22. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
[TBL] [Abstract][Full Text] [Related]
23. Identification of Rare Variants Predisposing to Thyroid Cancer.
Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
[No Abstract] [Full Text] [Related]
24. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
[TBL] [Abstract][Full Text] [Related]
25. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.
Moses W; Weng J; Kebebew E
Thyroid; 2011 Apr; 21(4):367-71. PubMed ID: 21190444
[TBL] [Abstract][Full Text] [Related]
26. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
[TBL] [Abstract][Full Text] [Related]
27. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
28. Comparison Between Clinicopathological Characteristics,
Yang T; Huang L; Chen C; Luo H; Jiang Y
Front Oncol; 2021; 11():616974. PubMed ID: 34926235
[TBL] [Abstract][Full Text] [Related]
29. Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).
Diquigiovanni C; Bonora E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946592
[TBL] [Abstract][Full Text] [Related]
30. A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.
Pires C; Marques IJ; Dias D; Saramago A; Leite V; Cavaco BM
Endocrine; 2021 Sep; 73(3):588-597. PubMed ID: 33683595
[TBL] [Abstract][Full Text] [Related]
31. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic features of familial nonmedullary thyroid carcinoma.
Fan YF; Zhang B; Yang X; Shang ZH; Liu HF; Xie Y; Liu YW; Gao WS; Wu Q; Li XY
Chin Med J (Engl); 2015 Apr; 128(8):1037-41. PubMed ID: 25881596
[TBL] [Abstract][Full Text] [Related]
33. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series.
Alsanea O; Wada N; Ain K; Wong M; Taylor K; Ituarte PH; Treseler PA; Weier HU; Freimer N; Siperstein AE; Duh QY; Takami H; Clark OH
Surgery; 2000 Dec; 128(6):1043-50;discussion 1050-1. PubMed ID: 11114641
[TBL] [Abstract][Full Text] [Related]
34. Mutant MYO1F alters the mitochondrial network and induces tumor proliferation in thyroid cancer.
Diquigiovanni C; Bergamini C; Evangelisti C; Isidori F; Vettori A; Tiso N; Argenton F; Costanzini A; Iommarini L; Anbunathan H; Pagotto U; Repaci A; Babbi G; Casadio R; Lenaz G; Rhoden KJ; Porcelli AM; Fato R; Bowcock A; Seri M; Romeo G; Bonora E
Int J Cancer; 2018 Oct; 143(7):1706-1719. PubMed ID: 29672841
[TBL] [Abstract][Full Text] [Related]
35. Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al.
Colombo C; Fugazzola L; Muzza M; Proverbio MC; Cirello V
Eur J Med Genet; 2018 Feb; 61(2):104-105. PubMed ID: 28779995
[TBL] [Abstract][Full Text] [Related]
36. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
38. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
39. Familial nonmedullary thyroid cancer: a case series in Iranian patients with a meta-review of case series.
Mohammadi Zaniani Z; Zeinalian M; Tabatabaiefar MA
Lab Med; 2023 Nov; ():. PubMed ID: 38007399
[TBL] [Abstract][Full Text] [Related]
40. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
